Episode Details
Back to Episodes
State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company's programs, including a new one to come
Published 1 year, 5 months ago
Description
He gives a brief overview of this approach, comments on recent competitor data in cancer, and highlights Kymera's STAT6 and TYK2 programs.